LV10309B - Method for enzymatic splitting of recombinant proteine with iga proteases, fusioned proteine,recombinant dna, cell - Google Patents

Method for enzymatic splitting of recombinant proteine with iga proteases, fusioned proteine,recombinant dna, cell Download PDF

Info

Publication number: LV10309B
Authority: LV; Latvia
Prior art keywords: pro; die; protein; der; von
Prior art date: 1990-02-03

Application number

LVP-93-1094A

Other languages

English (en)

Latvian (lv)

Other versions

LV10309A (lv

Inventor

Thomas F Meyer

Pohlner Johannes

Schumacher G Nter

Carola Dony

Original Assignee

Max Planck Ges Zur Firderung D

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-02-03

Filing date

1993-09-24

Publication date

1995-12-20

1990-05-17 Priority claimed from DE4015922A external-priority patent/DE4015922A1/de

1990-12-10 Priority claimed from DE4039415A external-priority patent/DE4039415A1/de

1993-09-24 Application filed by Max Planck Ges Zur Firderung D filed Critical Max Planck Ges Zur Firderung D

1994-10-20 Publication of LV10309A publication Critical patent/LV10309A/xx

1995-12-20 Publication of LV10309B publication Critical patent/LV10309B/lv

Links

230000002255 enzymatic effect Effects 0.000 title claims abstract description 4
239000004365 Protease Substances 0.000 title claims description 9
108020004511 Recombinant DNA Proteins 0.000 title claims description 9
108091005804 Peptidases Proteins 0.000 title claims description 8
238000000034 method Methods 0.000 title claims description 8
102000035195 Peptidases Human genes 0.000 title description 7
-1 fusioned proteine Proteins 0.000 title 1
108090000623 proteins and genes Proteins 0.000 claims abstract description 156
102000004169 proteins and genes Human genes 0.000 claims abstract description 145
108010002231 IgA-specific serine endopeptidase Proteins 0.000 claims abstract description 44
150000001413 amino acids Chemical class 0.000 claims abstract 6
125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
238000003776 cleavage reaction Methods 0.000 claims abstract 5
230000007017 scission Effects 0.000 claims abstract 5
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 39
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 39
108020004414 DNA Proteins 0.000 claims description 18
108090000765 processed proteins & peptides Proteins 0.000 claims description 14
230000014509 gene expression Effects 0.000 claims description 12
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 5
210000004027 cell Anatomy 0.000 claims description 4
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 2
230000007704 transition Effects 0.000 claims 3
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
210000001236 prokaryotic cell Anatomy 0.000 claims 1
238000010353 genetic engineering Methods 0.000 abstract 1
239000013598 vector Substances 0.000 description 29
230000012743 protein tagging Effects 0.000 description 23
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 20
239000000872 buffer Substances 0.000 description 19
108091034117 Oligonucleotide Proteins 0.000 description 15
241000588724 Escherichia coli Species 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
239000012634 fragment Substances 0.000 description 11
QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 10
108010077112 prolyl-proline Proteins 0.000 description 10
RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 9
239000013612 plasmid Substances 0.000 description 8
229930182817 methionine Natural products 0.000 description 7
230000004927 fusion Effects 0.000 description 6
210000003000 inclusion body Anatomy 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 5
241000894006 Bacteria Species 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 5
XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
108010087924 alanylproline Proteins 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
235000012054 meals Nutrition 0.000 description 5
244000005700 microbiome Species 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
102000009016 Cholera Toxin Human genes 0.000 description 4
108010049048 Cholera Toxin Proteins 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
108010048188 MS2 polymerase Proteins 0.000 description 4
241000588653 Neisseria Species 0.000 description 4
241001108452 Neisseria gonorrhoeae MS11 Species 0.000 description 4
FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 4
WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
108010026333 seryl-proline Proteins 0.000 description 4
102000029816 Collagenase Human genes 0.000 description 3
108060005980 Collagenase Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
102000000646 Interleukin-3 Human genes 0.000 description 3
108010002386 Interleukin-3 Proteins 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
108010090804 Streptavidin Proteins 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
229960002424 collagenase Drugs 0.000 description 3
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
229940076264 interleukin-3 Drugs 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
230000009466 transformation Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
108090000624 Cathepsin L Proteins 0.000 description 2
102000004172 Cathepsin L Human genes 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
108010074860 Factor Xa Proteins 0.000 description 2
241000233866 Fungi Species 0.000 description 2
ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
241001522306 Serinus serinus Species 0.000 description 2
239000008049 TAE buffer Substances 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
240000004922 Vigna radiata Species 0.000 description 2
235000010721 Vigna radiata var radiata Nutrition 0.000 description 2
235000011469 Vigna radiata var sublobata Nutrition 0.000 description 2
HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
108010060035 arginylproline Proteins 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
239000000835 fiber Substances 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000032258 transport Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
108091028026 C-DNA Proteins 0.000 description 1
101100119767 Caenorhabditis elegans fat-4 gene Proteins 0.000 description 1
101100468762 Caenorhabditis elegans ric-3 gene Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000003712 Complement factor B Human genes 0.000 description 1
108090000056 Complement factor B Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
244000182625 Dictamnus albus Species 0.000 description 1
101100396994 Drosophila melanogaster Inos gene Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010053070 Glutathione Disulfide Proteins 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
241001530812 Goupia glabra Species 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
241001501603 Haemophilus aegyptius Species 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
244000286779 Hansenula anomala Species 0.000 description 1
240000005979 Hordeum vulgare Species 0.000 description 1
235000007340 Hordeum vulgare Nutrition 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
240000006240 Linum usitatissimum Species 0.000 description 1
235000004431 Linum usitatissimum Nutrition 0.000 description 1
244000024873 Mentha crispa Species 0.000 description 1
235000014749 Mentha crispa Nutrition 0.000 description 1
102000009890 Osteonectin Human genes 0.000 description 1
108010077077 Osteonectin Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
NHDVNAKDACFHPX-GUBZILKMSA-N Pro-Arg-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O NHDVNAKDACFHPX-GUBZILKMSA-N 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
241000208465 Proteaceae Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
240000000278 Syzygium polyanthum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
239000012190 activator Substances 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
108010029539 arginyl-prolyl-proline Proteins 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
108090001092 clostripain Proteins 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000009713 electroplating Methods 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
239000000284 extract Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
206010039447 salmonellosis Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
101150061972 zur gene Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LVP-93-1094A 1990-02-03 1993-09-24 Method for enzymatic splitting of recombinant proteine with iga proteases, fusioned proteine,recombinant dna, cell LV10309B (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE4003149		1990-02-03
DE4015922A DE4015922A1 (de)	1990-05-17	1990-05-17	Verfahren zur enzymatischen prozessierung von proteinen unter verwendung von iga-proteasen (igase)
DE4015921		1990-05-17
DE4039415A DE4039415A1 (de)	1990-02-03	1990-12-10	Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest
PCT/EP1991/000192 WO1991011520A1 (de)	1990-02-03	1991-02-01	VERFAHREN ZUR ENZYMATISCHEN SPALTUNG REKOMBINANTER PROTEINE UNTER VERWENDUNG VON IgA-PROTEASEN

Publications (2)

Publication Number	Publication Date
LV10309A LV10309A (lv)	1994-10-20
LV10309B true LV10309B (en)	1995-12-20

Family

ID=27434868

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-93-1094A LV10309B (en)	1990-02-03	1993-09-24	Method for enzymatic splitting of recombinant proteine with iga proteases, fusioned proteine,recombinant dna, cell

Country Status (19)

Country	Link
US (1)	US5427927A (cs)
EP (2)	EP0513073B1 (cs)
JP (2)	JPH0789952B2 (cs)
KR (1)	KR960011919B1 (cs)
AT (2)	ATE124456T1 (cs)
AU (1)	AU638309B2 (cs)
CA (1)	CA2074943C (cs)
CZ (1)	CZ284774B6 (cs)
DK (1)	DK0513073T3 (cs)
ES (2)	ES2076521T3 (cs)
FI (1)	FI109810B (cs)
HU (1)	HU217103B (cs)
IE (1)	IE64938B1 (cs)
IL (1)	IL97119A0 (cs)
LV (1)	LV10309B (cs)
NO (1)	NO311142B1 (cs)
NZ (1)	NZ236819A (cs)
PT (1)	PT96658B (cs)
WO (1)	WO1991011520A1 (cs)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5718893A (en) *	1984-04-15	1998-02-17	Foster; Preston F.	Use of G-CSF to reduce acute rejection
DE4344350C2 (de) *	1993-12-23	1995-09-21	Max Planck Gesellschaft	Bakterien zur Herstellung stabiler Fusionsproteine und Verfahren zu deren Nachweis
US5536495A (en) *	1994-04-15	1996-07-16	Foster; Preston F.	Use of G-CSF to reduce acute rejection
WO1996009395A2 (de) *	1994-09-21	1996-03-28	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Arzneimittel zur prophylaxe und behandlung von und diagnostika zur erkennung von autoimmunkrankheiten und viralen erkrankungen
AT404838B (de) *	1995-11-24	1999-03-25	Immuno Ag	Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
DE19549232C2 (de) *	1995-12-20	1998-05-20	Boehringer Mannheim Gmbh	Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
GB9618960D0 (en)	1996-09-11	1996-10-23	Medical Science Sys Inc	Proteases
US6444202B1 (en)	1996-11-25	2002-09-03	Bundesrepublic Deutschland, Vertreten Durch Den Bundesminister Fur Gesundheit	Processed polypeptides with IL-16 activity, processes for their production and their use
US20030190740A1 (en) *	1998-10-13	2003-10-09	The University Of Georgia Research Foundation, Inc	Stabilized bioactive peptides and methods of identification, synthesis, and use
KR20020002354A (ko) *	1998-10-13	2002-01-09	추후제출	안정화된 생활성 펩티드 및 이들을 동정, 합성 및이용하는 방법
KR100356140B1 (ko) *	1999-07-08	2002-10-19	한미약품공업 주식회사	인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US20030190644A1 (en) *	1999-10-13	2003-10-09	Andreas Braun	Methods for generating databases and databases for identifying polymorphic genetic markers
CA2507189C (en) *	2002-11-27	2018-06-12	Sequenom, Inc.	Fragmentation-based methods and systems for sequence variation detection and discovery
NZ561162A (en)	2003-04-23	2009-11-27	Hoffmann La Roche	Human granzyme B protease variant wherein cystein 228 is mutated to phenylalanine
CA2523490A1 (en) *	2003-04-25	2004-11-11	Sequenom, Inc.	Fragmentation-based methods and systems for de novo sequencing
WO2005024068A2 (en) *	2003-09-05	2005-03-17	Sequenom, Inc.	Allele-specific sequence variation analysis
KR20060116825A (ko)	2003-10-23	2006-11-15	일루미겐 바이오사이언시스, 인코포레이티드	바이러스 감염에 대한 저항성과 관련된 유전자인ｏａｓ1에서의 돌연변이의 검출
US7220407B2 (en)	2003-10-27	2007-05-22	Amgen Inc.	G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
SI21639A (sl) *	2003-12-23	2005-06-30	LEK farmacevtska dru�ba d.d.	Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
US7608394B2 (en)	2004-03-26	2009-10-27	Sequenom, Inc.	Methods and compositions for phenotype identification based on nucleic acid methylation
US9249456B2 (en) *	2004-03-26	2016-02-02	Agena Bioscience, Inc.	Base specific cleavage of methylation-specific amplification products in combination with mass analysis
CN101072882A (zh) *	2004-09-10	2007-11-14	塞昆纳姆股份有限公司	用于核酸长程序列分析的方法
ATE544463T1 (de)	2004-11-05	2012-02-15	Univ Northwestern	Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
UA95446C2 (ru)	2005-05-04	2011-08-10	Іллюміджен Байосайєнсіз, Інк.	Мутаци в генах oas1
CN101484469B (zh) *	2006-08-31	2012-12-12	弗·哈夫曼-拉罗切有限公司	生产胰岛素样生长因子-ⅰ的方法
CL2007002502A1 (es)	2006-08-31	2008-05-30	Hoffmann La Roche	Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
WO2008128111A1 (en) *	2007-04-13	2008-10-23	Sequenom, Inc.	Comparative sequence analysis processes and systems
DE202007018629U1 (de)	2007-08-27	2008-12-24	Biogenerix Ag	Flüssigformulierung von G-CSF
PT2076243E (pt)	2007-08-27	2014-12-05	Ratiopharm Gmbh	Formulação líquida de g-csf
US8501449B2 (en) *	2007-12-04	2013-08-06	Proteon Therapeutics, Inc.	Recombinant elastase proteins and methods of manufacturing and use thereof
AU2009231394B2 (en) *	2008-04-03	2013-09-05	F. Hoffmann-La Roche Ag	Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders
KR20100119899A (ko) *	2008-04-03	2010-11-11	에프. 호프만-라 로슈 아게	폴리에틸렌글리콜화된 인슐린 유사 성장 인자 분석법
US8053222B2 (en) *	2009-02-12	2011-11-08	Academia Sinica, Taiwan	Protein expression system involving mutated severe respiratory syndrome-associated coronavirus 3C-like protease
US20110152188A1 (en) *	2009-12-23	2011-06-23	Hanns-Christian Mahler	Pharmaceutical compositions of igf/i proteins
US9867777B2 (en)	2010-01-19	2018-01-16	Hanmi Science Co., Ltd.	Liquid formulations for long-acting G-CSF conjugate
WO2012028523A2 (en) *	2010-08-30	2012-03-08	F. Hoffmann-La Roche Ag	Prokaryotic expression construct
CN105247067A (zh) *	2013-05-24	2016-01-13	诺和诺德股份有限公司	融合蛋白酶
WO2015091144A1 (en) *	2013-12-20	2015-06-25	F. Hoffmann-La Roche Ag	Improved recombinant polypeptide production methods
CR20210429A (es)	2015-06-24	2021-09-24	Hoffmann La Roche	ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI819458B (zh)	2015-10-02	2023-10-21	瑞士商赫孚孟拉羅股份公司	雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
WO2018225824A1 (ja) *	2017-06-09	2018-12-13	三菱電機株式会社	フェーズドアレイアンテナ
JP7736395B1 (ja) *	2024-02-29	2025-09-09	積水メディカル株式会社	免疫学的測定方法、免疫学的測定用試薬、免疫学的測定用検体前処理液、免疫学的測定用試薬キット、及び非特異反応抑制剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL60184A (en) *	1979-05-31	1984-05-31	Schering Ag	Process for the specific cleavage of protein sequences from proteins
JPS62129298A (ja) *	1985-12-02	1987-06-11	Chugai Pharmaceut Co Ltd	新規ポリペプチド
DE3680613D1 (de) *	1985-02-08	1991-09-05	Chugai Pharmaceutical Co Ltd	Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
US5087564A (en) *	1985-06-20	1992-02-11	Monsanto Company	Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3681551D1 (de) *	1985-09-30	1991-10-24	Chugai Pharmaceutical Co Ltd	Menschlicher granulozyten-colony stimulierender faktor.
DE3545568A1 (de) *	1985-12-21	1987-07-16	Hoechst Ag	Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
FR2594846B1 (fr) *	1986-02-21	1989-10-20	Genetica	Procede de preparation de la serum albumine humaine mature
US4828988A (en) *	1986-05-15	1989-05-09	Smith Kline - Rit	Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine
DE3622221A1 (de) *	1986-07-02	1988-01-14	Max Planck Gesellschaft	Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen
JPH01500483A (ja) *	1986-08-11	1989-02-23	シタス　コーポレイション	Ｇ‐ｃｓｆ及びそのミューテインの発現
IT1223577B (it) *	1987-12-22	1990-09-19	Eniricerche Spa	Procedimento migliorato per la preparazione dell'ormone della crescita umano naturale in forma pura
ATE111921T1 (de) *	1988-06-03	1994-10-15	Chugai Pharmaceutical Co Ltd	Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
EP0446283A4 (en) *	1988-12-01	1992-01-08	Univ North Carolina	Synthetic interleukin-6
US5055555A (en) *	1989-01-05	1991-10-08	Helmut Sassenfeld	Purification of G-CSF
US5073627A (en) *	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3

1991
- 1991-01-18 NZ NZ236819A patent/NZ236819A/xx unknown
- 1991-01-31 IL IL97119A patent/IL97119A0/xx not_active IP Right Cessation
- 1991-02-01 JP JP3503102A patent/JPH0789952B2/ja not_active Expired - Lifetime
- 1991-02-01 CA CA002074943A patent/CA2074943C/en not_active Expired - Lifetime
- 1991-02-01 IE IE35891A patent/IE64938B1/en not_active IP Right Cessation
- 1991-02-01 ES ES91902956T patent/ES2076521T3/es not_active Expired - Lifetime
- 1991-02-01 DK DK91902956.1T patent/DK0513073T3/da active
- 1991-02-01 EP EP91902956A patent/EP0513073B1/de not_active Expired - Lifetime
- 1991-02-01 WO PCT/EP1991/000192 patent/WO1991011520A1/de not_active Ceased
- 1991-02-01 EP EP93121015A patent/EP0602688B1/de not_active Expired - Lifetime
- 1991-02-01 ES ES93121015T patent/ES2177536T3/es not_active Expired - Lifetime
- 1991-02-01 AT AT91902956T patent/ATE124456T1/de not_active IP Right Cessation
- 1991-02-01 CZ CS91241A patent/CZ284774B6/cs not_active IP Right Cessation
- 1991-02-01 PT PT96658A patent/PT96658B/pt not_active IP Right Cessation
- 1991-02-01 AU AU71496/91A patent/AU638309B2/en not_active Ceased
- 1991-02-01 KR KR1019920701858A patent/KR960011919B1/ko not_active Expired - Lifetime
- 1991-02-01 HU HU9202511A patent/HU217103B/hu unknown
- 1991-02-01 US US07/917,034 patent/US5427927A/en not_active Expired - Lifetime
- 1991-02-01 AT AT93121015T patent/ATE219518T1/de not_active IP Right Cessation
1992
- 1992-07-30 NO NO19923010A patent/NO311142B1/no unknown
- 1992-07-31 FI FI923463A patent/FI109810B/fi active
1993
- 1993-09-24 LV LVP-93-1094A patent/LV10309B/lv unknown
1995
- 1995-01-04 JP JP7000120A patent/JP2766621B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0513073A1 (de)	1992-11-19
IL97119A0 (en)	1992-03-29
FI923463A0 (fi)	1992-07-31
ES2076521T3 (es)	1995-11-01
JPH07278195A (ja)	1995-10-24
EP0513073B1 (de)	1995-06-28
ATE124456T1 (de)	1995-07-15
EP0602688B1 (de)	2002-06-19
IE64938B1 (en)	1995-09-20
NO923010D0 (no)	1992-07-30
HU217103B (hu)	1999-11-29
FI109810B (fi)	2002-10-15
ES2177536T3 (es)	2002-12-16
JP2766621B2 (ja)	1998-06-18
EP0602688A1 (en)	1994-06-22
NZ236819A (en)	1993-07-27
PT96658A (pt)	1991-10-31
LV10309A (lv)	1994-10-20
JPH0789952B2 (ja)	1995-10-04
CA2074943C (en)	1999-12-07
ATE219518T1 (de)	2002-07-15
FI923463L (fi)	1992-07-31
CZ284774B6 (cs)	1999-02-17
DK0513073T3 (da)	1995-10-30
AU7149691A (en)	1991-08-21
AU638309B2 (en)	1993-06-24
NO923010L (no)	1992-09-14
HU9202511D0 (en)	1992-10-28
US5427927A (en)	1995-06-27
KR960011919B1 (ko)	1996-09-04
JPH05501360A (ja)	1993-03-18
NO311142B1 (no)	2001-10-15
WO1991011520A1 (de)	1991-08-08
PT96658B (pt)	1998-09-30
HUT63195A (en)	1993-07-28
CA2074943A1 (en)	1991-08-04
CS9100241A2 (en)	1991-08-13
IE910358A1 (en)	1991-08-14

Publication	Publication Date	Title
EP0513073B1 (de)	1995-06-28	VERFAHREN ZUR ENZYMATISCHEN SPALTUNG REKOMBINANTER PROTEINE UNTER VERWENDUNG VON IgA-PROTEASEN
DE3050722C2 (cs)	1987-09-24
DE3111405C2 (cs)	1990-06-21
DE3785864T2 (de)	1994-01-20	Verfahren zur Herstellung von menschlichem Epidermalwachstumsfaktor und dessen Analogen.
DE3486216T2 (de)	1994-02-17	Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
DE3687763T2 (de)	1993-06-09	Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.
DE3382575T2 (de)	1993-02-11	Dna-sequenzen, rekombinante dna-molekuele und verfahren zur herstellung von schweinewachstumshormonaehnlichen polypeptiden.
DD203330A5 (de)	1983-10-19	Verfahren zur herstellung hybrider human-leukozyten-interferone
DD209652A5 (de)	1984-05-16	Verfahren zur herstellung eines replikablen vektors
CH663619A5 (de)	1987-12-31	Polypeptide, welche die aminosaeuresequenz und die biologische aktivitaet von reifem human-immuninterferon aufweisen.
DD203071A5 (de)	1983-10-12	Verfahren zur herstellung von rekombinant-dna-molekuele
DD291093A5 (de)	1991-06-20	Recombinierende dna-sequenzen und ihr verfahren zur herstellung des menschlichen proapolipoprotein a-i
CH663032A5 (de)	1987-11-13	Doppelstraengige dna, replizierbare plasmidische expressionstraeger zur mikrobiellen herstellung von hybrid human-leukozyten-interferon und transformierte mikroorganismen.
DE69434909T3 (de)	2012-02-09	Herstellung von humaninsulin
AT389892B (de)	1990-02-12	Dna-sequenz mit einem gen, das fuer human-interleukin-2 codiert
DD283837A5 (de)	1990-10-24	Verfahren zur herstellung eines rekombinanten dna-molekuels
DD246318A5 (de)	1987-06-03	Neue genetische Sequenzen, die durch die codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
EP0222366A2 (de)	1987-05-20	Verfahren zur Herstellung von Humanlysozym
DE68913846T3 (de)	2002-10-02	Expressionssystem.
DD208989A5 (de)	1984-04-18	Verfahren zur synthetisierung von menschlichem insulin
DE68907166T2 (de)	1993-10-21	Verfahren zur Herstellung von menschlichem Lysozym.
DE69033772T2 (de)	2002-06-20	Verbesserte plasmidvektoren für zelluläre schleimpilze der gattung dictyostelium
EP1051495B1 (de)	2006-01-25	Rekombinante mistellektine
DE3783305T2 (de)	1993-05-19	Expressionsvektor fuer menschlichen insulinaehnlichen wachstumsfaktor-i.
DE69023655T2 (de)	1996-05-02	Verfahren zur Isolierung und Expression eines für Streptokinase kodierenden Gens, Nukleotidsequenz, rekombinante DNA und transformierter Mikroorganismus.